company background image
6LUA logo

NVN Liquidation DB:6LUA Stock Report

Last Price

€0.001

Market Cap

€5.1k

7D

0%

1Y

-99.9%

Updated

17 Dec, 2023

Data

Company Financials

6LUA Stock Overview

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases.

6LUA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

NVN Liquidation, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NVN Liquidation
Historical stock prices
Current Share PriceUS$0.001
52 Week HighUS$1.97
52 Week LowUS$0.001
Beta-0.24
1 Month Change0%
3 Month Change-97.78%
1 Year Change-99.92%
3 Year Change-99.98%
5 Year Change-99.99%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Shareholder Returns

6LUADE PharmaceuticalsDE Market
7D0%4.0%2.5%
1Y-99.9%-24.6%7.0%

Return vs Industry: 6LUA underperformed the German Pharmaceuticals industry which returned -26.5% over the past year.

Return vs Market: 6LUA underperformed the German Market which returned 9.5% over the past year.

Price Volatility

Is 6LUA's price volatile compared to industry and market?
6LUA volatility
6LUA Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 6LUA's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 6LUA's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200690n/ahttps://www.novan.com

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete’s foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2.

NVN Liquidation, Inc. Fundamentals Summary

How do NVN Liquidation's earnings and revenue compare to its market cap?
6LUA fundamental statistics
Market cap€5.14k
Earnings (TTM)-€29.40m
Revenue (TTM)€22.86m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6LUA income statement (TTM)
RevenueUS$24.92m
Cost of RevenueUS$24.45m
Gross ProfitUS$473.00k
Other ExpensesUS$32.52m
Earnings-US$32.05m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.14
Gross Margin1.90%
Net Profit Margin-128.61%
Debt/Equity Ratio-1,164.1%

How did 6LUA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.